Treatment of hepatitis C virus (HCV) infection has experienced a major advancement with
the advent of the new direct acting antivirals (DAA). Current HCV infection cure rates exceed …

Background & Aims The success of direct-acting antivirals (DAA) against hepatitis C is a
major breakthrough in hepatology. Until now, however, there are very few data on the effect …

Hepatocellular carcinoma (HCC) is a common, life-threatening complication of longstanding
infection with the hepatitis C virus (HCV), likely a consequence of the direct oncogenic …

Background Data on HCV‐related hepatocellular carcinoma (HCC) early recurrence in
patients whose HCC was previously cured, and subsequently treated by direct‐acting …

Although studies suggest decreased incident hepatocellular carcinoma (HCC) after
treatment with direct-acting antivirals (DAAs) for hepatitis C virus (HCV) infection, data are …

Antiviral therapy with interferon based therapies (IBT) has shown potential in improving
survival in patients who have undergone resection or locoregional therapy for hepatitis C …

Background & Aims Hepatocellular carcinoma (HCC) represents a serious complication of
HCV-related cirrhosis. New direct-acting antivirals (DAA) cure HCV infection in over 90% of …

Dr Reig and colleagues report a single centre study [1], evaluating the benefit of direct
antiviral agent (DAA) based therapies (12/24 weeks regimens). The effect was measured on …

Background & Aims Previous studies have reported a high frequency of hepatocellular
carcinoma (HCC) occurrence in patients with advanced liver disease, after receipt of …

Background & Aims The effectiveness of direct-acting antivirals (DAAs) against hepatitis C
virus (HCV), following successful treatment of early hepatocellular carcinoma (HCC), has …